Long-term safety of glycopyrrolate: A randomized study of COPD patients
August 9th 2016Glycopyrrolate bromide is a quick-onset long-acting muscarinic antagonist bronchodilator with FDA approval for use as maintenance treatment of COPD. Seebri Neohaler is approved for use at a dose of 15.6 ug inhaled twice daily.